Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp (NASDAQ: DRIO) is a leader in digital therapeutics, revolutionizing chronic condition management through data-driven health solutions. This news hub provides investors and healthcare professionals with essential updates on corporate milestones, clinical validations, and strategic partnerships.
Access timely press releases covering earnings reports, product innovations, and business expansions. Our curated collection includes updates on Dario's integrated platform developments, partnership announcements with healthcare providers, and regulatory milestones in digital health.
Key focus areas include advancements in personalized coaching technologies, behavioral health integrations, and outcomes from clinical studies. Stay informed about DarioHealth's progress in merging life sciences with digital tools to improve chronic care management for employers, payers, and patients.
Bookmark this page for direct access to verified corporate communications. Check regularly for updates on DRIO's market-moving developments in the rapidly evolving digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) has secured a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s starting in Q3 2024. The solution addresses multiple health conditions, including diabetes, pre-diabetes, hypertension, and weight management.
Dario's platform is designed to drive sustainable behavior change, which is important for the success of GLP-1 medications, as 68% of users discontinue within a year. The company's enhanced engagement capabilities, bolstered by its acquisition of Twill, offer personalized journeys and behavioral support.
Dario expects at least ten employer clients to adopt its integrated offering in the coming quarter, leveraging its multi-chronic condition platform. The company sees growing interest from employers, payers, and pharmaceutical companies in its combined Dario-Twill solution for managing GLP-1 challenges.
New research presented by DarioHealth at the 84th Annual ADA Scientific Sessions demonstrates the efficacy of their digital health platform in sustaining behavior change for members taking GLP-1 medications. Data over a 12-month period show significant improvements in healthy lifestyle tracking and blood glucose control. Notably, 31% of Type 2 diabetes members achieved results consistent with diabetes remission. This research underscores the importance of combining GLP-1 medications with effective digital health solutions to maximize outcomes.
DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic reorganization aimed at accelerating commercialization and profitability. The company has transitioned to a flatter organizational model by eliminating the President role and creating dedicated C-level positions for each core function. Steven Nelson has been appointed as the inaugural Chief Commercial Officer (CCO) to drive global commercial activities, including sales, marketing, client management, and strategic partnerships.
Nelson brings over two decades of experience in scaling technology-centric healthcare companies, including leadership roles at Contigo Health and Anthem Inc. His compensation includes stock options tied to performance targets, emphasizing the importance of reaching specific revenue goals.
This reorganization seeks to maximize customer impact and strengthen DarioHealth's position in the digital health market, capitalizing on expanded product offerings and commercial opportunities.
DarioHealth (NASDAQ: DRIO) reported first quarter 2024 revenue of $5.8 million, up 59% from Q4 2023 but down 18.5% year-over-year due to milestone-driven revenues. Their core B2B2C channel saw revenues of $3.47 million, an increase of 176% YoY, driven by new customers and the Twill acquisition. Gross profit was $2.4 million, a decline from $3.1 million YoY, but improved from the previous quarter. Operating expenses rose to $20.3 million, driven by the acquisition. The net loss was $7.2 million, a 44% decrease YoY. The company anticipates breakeven by H2 2025, supported by cost synergies and expanding high-margin revenue streams.
DarioHealth Corp. (Nasdaq: DRIO) will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time with Erez Raphael, Chief Executive Officer, and Rick Anderson, President, as hosts.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
